SI3316909T1 - Protitelesa anti-ntb-a ter povezane sestavine in metode - Google Patents

Protitelesa anti-ntb-a ter povezane sestavine in metode

Info

Publication number
SI3316909T1
SI3316909T1 SI201631741T SI201631741T SI3316909T1 SI 3316909 T1 SI3316909 T1 SI 3316909T1 SI 201631741 T SI201631741 T SI 201631741T SI 201631741 T SI201631741 T SI 201631741T SI 3316909 T1 SI3316909 T1 SI 3316909T1
Authority
SI
Slovenia
Prior art keywords
ntb
antibodies
methods
related compositions
compositions
Prior art date
Application number
SI201631741T
Other languages
English (en)
Inventor
Timothy Lewis
Lori Westendorf
Django Sussman
Che-Leung Law
Original Assignee
Seagen Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Seagen Inc. filed Critical Seagen Inc.
Publication of SI3316909T1 publication Critical patent/SI3316909T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
SI201631741T 2015-06-30 2016-06-30 Protitelesa anti-ntb-a ter povezane sestavine in metode SI3316909T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562186596P 2015-06-30 2015-06-30
US201662321849P 2016-04-13 2016-04-13
EP16818762.3A EP3316909B1 (en) 2015-06-30 2016-06-30 Anti-ntb-a antibodies and related compositions and methods
PCT/US2016/040307 WO2017004330A1 (en) 2015-06-30 2016-06-30 Anti-ntb-a antibodies and related compositions and methods

Publications (1)

Publication Number Publication Date
SI3316909T1 true SI3316909T1 (sl) 2023-10-30

Family

ID=57609137

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631741T SI3316909T1 (sl) 2015-06-30 2016-06-30 Protitelesa anti-ntb-a ter povezane sestavine in metode

Country Status (22)

Country Link
US (2) US11351269B2 (sl)
EP (2) EP4302784A3 (sl)
JP (2) JP6879947B2 (sl)
KR (1) KR20180021705A (sl)
CN (2) CN107735105B (sl)
AU (2) AU2016287647A1 (sl)
BR (1) BR112017027498A2 (sl)
CA (1) CA2986796A1 (sl)
DK (1) DK3316909T3 (sl)
EA (1) EA201890158A1 (sl)
ES (1) ES2955961T3 (sl)
FI (1) FI3316909T3 (sl)
HK (1) HK1253306A1 (sl)
HU (1) HUE063320T2 (sl)
IL (2) IL303690A (sl)
MX (1) MX2017017049A (sl)
PL (1) PL3316909T3 (sl)
PT (1) PT3316909T (sl)
SG (1) SG10202005460RA (sl)
SI (1) SI3316909T1 (sl)
WO (1) WO2017004330A1 (sl)
ZA (1) ZA201707869B (sl)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA031025B1 (ru) * 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
US11351269B2 (en) 2015-06-30 2022-06-07 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
TW202405006A (zh) 2017-09-29 2024-02-01 日商第一三共股份有限公司 抗體－吡咯并苯二氮呯衍生物複合體
SG11202104993SA (en) 2018-11-14 2021-06-29 Daiichi Sankyo Co Ltd Anti-cdh6 antibody-pyrrolobenzodiazepine derivative conjugate
WO2020196475A1 (ja) 2019-03-25 2020-10-01 第一三共株式会社 抗ｈｅｒ２抗体－ピロロベンゾジアゼピン誘導体コンジュゲート
EP3950061A4 (en) 2019-03-25 2022-11-16 Daiichi Sankyo Company, Limited ANTIBODY PYRROLOBENZODIAZEPINE DERIVATIVE CONJUGATE
CA3139180A1 (en) 2019-03-27 2020-10-01 Daiichi Sankyo Company, Limited Combination of antibody-pyrrolobenzodiazepine derivative conjugate and parp inhibitor
EP3994172A1 (en) 2019-07-03 2022-05-11 Oxford BioTherapeutics Ltd Antibodies and methods of use
WO2021067820A1 (en) 2019-10-04 2021-04-08 Seagen Inc. Formulation of antibody-drug conjugate
CA3152316A1 (en) 2019-10-04 2021-04-08 Scott C. Jeffrey Camptothecin peptide conjugates
EP4069374A1 (en) * 2019-12-06 2022-10-12 Thoas Fioretos Novel agents and uses thereof
EP4132588A1 (en) 2020-04-10 2023-02-15 Seagen Inc. Charge variant linkers
AU2021338014A1 (en) 2020-09-02 2023-03-09 Daiichi Sankyo Company, Limited Novel endo-β-N-acetylglucosaminidase
EP4277664A1 (en) 2021-01-13 2023-11-22 Memorial Sloan Kettering Cancer Center Antibody-pyrrolobenzodiazepine derivative conjugate
EP4326333A1 (en) 2021-04-20 2024-02-28 Seagen Inc. Modulation of antibody-dependent cellular cytotoxicity
AU2022283467A1 (en) 2021-05-28 2023-12-07 Seagen Inc. Anthracycline antibody conjugates
US20230381321A1 (en) 2022-03-17 2023-11-30 Seagan Inc., Camptothecin conjugates

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4880935A (en) 1986-07-11 1989-11-14 Icrf (Patents) Limited Heterobifunctional linking agents derived from N-succinimido-dithio-alpha methyl-methylene-benzoates
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2 Inc Geänderte antikörper.
IL89220A (en) 1988-02-11 1994-02-27 Bristol Myers Squibb Co Immunoconjugates of anthracycline, their production and pharmaceutical preparations containing them
EP0368684B2 (en) 1988-11-11 2004-09-29 Medical Research Council Cloning immunoglobulin variable domain sequences.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
LU91067I2 (fr) 1991-06-14 2004-04-02 Genentech Inc Trastuzumab et ses variantes et dérivés immuno chimiques y compris les immotoxines
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
ES2195036T3 (es) 1995-12-22 2003-12-01 Bristol Myers Squibb Co Conectores de hidrazona ramificados.
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
CN100489892C (zh) 1999-02-05 2009-05-20 三星电子株式会社 恢复描述图像的纹理特征的图像纹理描述符的方法及装置
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
EP1545613B9 (en) 2002-07-31 2012-01-25 Seattle Genetics, Inc. Auristatin conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
SG195524A1 (en) 2003-11-06 2013-12-30 Seattle Genetics Inc Monomethylvaline compounds capable of conjugation to ligands
DE10355904A1 (de) * 2003-11-29 2005-06-30 Merck Patent Gmbh Feste Formen von anti-EGFR-Antikörpern
NZ552480A (en) 2004-07-30 2010-01-29 Rinat Neuroscience Corp Antibodies directed against amyloid-beta peptide and methods of using same
WO2007008603A1 (en) 2005-07-07 2007-01-18 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine side-chain modifications at the c-terminus
US8871720B2 (en) 2005-07-07 2014-10-28 Seattle Genetics, Inc. Monomethylvaline compounds having phenylalanine carboxy modifications at the C-terminus
RU2009107707A (ru) * 2006-08-04 2010-09-10 Новартис АГ (CH) СПЕЦИФИЧНОЕ К EphB3 АНТИТЕЛО И ЕГО ПРИМЕНЕНИЕ
WO2008027739A2 (en) * 2006-08-28 2008-03-06 Nuvelo, Inc. Antibodies to ntb-a
ES2523915T5 (es) 2006-12-01 2022-05-26 Seagen Inc Agentes de unión a la diana variantes y usos de los mismos
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
KR101671360B1 (ko) 2010-04-15 2016-11-01 시애틀 지네틱스, 인크. 표적화된 피롤로벤조디아제핀 접합체
WO2013173493A1 (en) 2012-05-15 2013-11-21 Manikkam Suthanthiran Non-invasive method of diagnosing renal fibrosis
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
SI2906296T1 (sl) 2012-10-12 2018-06-29 Adc Therapeutics Sa Pirolobenzodiazepin-protitelesni konjugati
EA031025B1 (ru) * 2012-12-21 2018-11-30 Сиэтл Дженетикс, Инк. Антитела против ntb-a и связанные с ними композиции и способы
SG10201707233UA (en) * 2013-03-14 2017-10-30 Shionogi & Co Monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
WO2015095002A1 (en) * 2013-12-16 2015-06-25 Texas Tech University System Anti-ron monoclonal antibodies as a cytotoxic drug delivery system for targeted cancer therapy
TWI734410B (zh) * 2014-09-11 2021-07-21 日商塩野義製藥股份有限公司 阻礙血管內皮脂酶之酵素活性的人類化單株抗體
US11351269B2 (en) 2015-06-30 2022-06-07 Seagen Inc. Anti-NTB-A antibodies and related compositions and methods
EP3442584B1 (en) 2016-03-15 2021-07-28 Seagen Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors

Also Published As

Publication number Publication date
WO2017004330A1 (en) 2017-01-05
IL303690A (en) 2023-08-01
AU2022209203A1 (en) 2022-09-15
SG10202005460RA (en) 2020-07-29
EP3316909B1 (en) 2023-08-30
US20230218776A1 (en) 2023-07-13
IL256295B2 (en) 2023-11-01
MX2017017049A (es) 2018-03-06
EP4302784A2 (en) 2024-01-10
EP4302784A3 (en) 2024-03-13
HUE063320T2 (hu) 2024-01-28
AU2016287647A1 (en) 2017-12-07
US20180169257A1 (en) 2018-06-21
IL256295B1 (en) 2023-07-01
EP3316909A4 (en) 2019-01-09
CN107735105A (zh) 2018-02-23
PL3316909T3 (pl) 2023-11-20
HK1253306A1 (zh) 2019-06-14
FI3316909T3 (fi) 2023-09-07
ES2955961T3 (es) 2023-12-11
EA201890158A1 (ru) 2018-06-29
ZA201707869B (en) 2023-10-25
US11351269B2 (en) 2022-06-07
DK3316909T3 (da) 2023-11-13
KR20180021705A (ko) 2018-03-05
CA2986796A1 (en) 2017-01-05
PT3316909T (pt) 2023-11-22
JP2018520671A (ja) 2018-08-02
JP7194762B2 (ja) 2022-12-22
BR112017027498A2 (pt) 2018-09-11
JP6879947B2 (ja) 2021-06-02
CN116063502A (zh) 2023-05-05
CN107735105B (zh) 2022-09-16
EP3316909A1 (en) 2018-05-09
IL256295A (en) 2018-02-28
JP2021087427A (ja) 2021-06-10

Similar Documents

Publication Publication Date Title
IL265844A (en) Anti-lag-3 antibodies and preparations
IL262176A (en) Anti-tim-3 antibodies and preparations
HK1257295A1 (zh) 用於免疫腫瘤學的組合物和方法
HK1254861A1 (zh) 抗lag3抗體及其用途
HK1253306A1 (zh) 抗ntb-a抗體及相關組合物和方法
HK1252615A1 (zh) Il-8-結合抗體及其應用
HK1249911A1 (zh) 抗muc16抗體及其應用
HK1250238A1 (zh) 抗angptl8抗體及其用途
GB2546350B (en) Compositions and methods
HK1256381A1 (zh) 抗pacap抗體及其用途
GB201718876D0 (en) Antithrombin-heparin compositions and methods
HK1245158A1 (zh) 阿吡莫德組合物及其使用方法
GB201503387D0 (en) Anti-carbapenem antibodies and uses thereof
HK1254240A1 (zh) 抗羥腐胺賴氨酸抗體及其用途
GB201705626D0 (en) Compositions and methods
ZA201807665B (en) Methods and compositions
GB201715820D0 (en) Compositions and methods
GB201512996D0 (en) Compositions and methods
GB201514413D0 (en) Compositions and methods
ZA201807782B (en) Methods and compositions
IL256261B (en) Hide1 compositions and methods
GB201522554D0 (en) Methods and compositions
GB201518167D0 (en) Methods and compositions
GB201514415D0 (en) Compositions and methods